Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,985 active trials259 approved drugs4,032 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02857608 | A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus | withdrawn | Phase 2 | 0 | Cardinal Health 414, LLCINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT02274012 | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 14, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT01895790 | Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01087580 | Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | withdrawn | Phase 2 | 0 | Boston Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Feb 14, 2017 | clinicaltrials |
| NCT02950038 | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 13, 2017 | clinicaltrials |
| NCT00881595 | Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas(SA02) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | Feb 10, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02343679 | Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies | withdrawn | Phase 2 | 0 | Anne Beaven, MDOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | withdrawn | Phase 2 | 0 | California Pacific Medical Center Research InstituteOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02965417 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | withdrawn | Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Feb 1, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | withdrawn | Phase 2 | 0 | Osama Rahma, MDOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT00471835 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Jan 19, 2017 | clinicaltrials |
| NCT02785068 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Merrimack PharmaceuticalsINDUSTRY | 0 | Jan 11, 2017 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT03005015 | Lenvatinib in Second Line Endometrial Carcinoma | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant(CARAMEL 2) | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00452920 | Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00881387 | Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00450515 | Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT02420938 | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. | withdrawn | Phase 1 / Phase 2 | 0 | Stanford UniversityOTHER | 0 | Dec 1, 2016 | clinicaltrials |
| NCT01522677 | A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Edward NelsonOTHER | 1 | Dec 1, 2016 | clinicaltrials |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Medivation, Inc.INDUSTRY | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02645591 | Randomized AmnioFix Study During Radical Prostatectomy | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 22, 2016 | clinicaltrials |
| NCT02906605 | A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 22, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02756663 | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma(PANORAMA-5) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 8, 2016 | clinicaltrials |
| NCT01244009 | A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) | withdrawn | Phase 2 | 0 | Tesaro, Inc.INDUSTRY | 0 | Nov 7, 2016 | clinicaltrials |
| NCT01423539 | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | withdrawn | Phase 2 | 0 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02115126 | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant | withdrawn | Phase 2 | 0 | David Rizzieri, MDOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2016 | clinicaltrials |
| NCT02656563 | Radium 223 Following Intermittent ADT(RAND) | withdrawn | Phase 2 | 0 | Canadian Urology Research ConsortiumOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02610621 | Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Loyola UniversityOTHER | 0 | Oct 12, 2016 | clinicaltrials |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02367651 | Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Oct 12, 2016 | clinicaltrials |
| NCT02141100 | Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Kjeld SchmiegelowOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT01045941 | Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2016 | clinicaltrials |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Mar 15, 2017source: clinicaltrials